Labcorp (NYSE:LH) Releases FY 2026 Earnings Guidance

Labcorp (NYSE:LH) issued an update on its FY 2026 earnings guidance on Friday. The company provided earnings per share guidance of 18.100-18.550 for the period, compared to the consensus EPS estimate of 18.340. The company issued revenue guidance of $14.7 billion-$14.8 billion, compared to the consensus revenue estimate of $14.7 billion.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Piper Sandler lifted their price objective on shares of Labcorp from $300.00 to $309.00 and gave the company a “neutral” rating in a report on Tuesday, August 4th. Weiss Ratings upgraded shares of Labcorp from a “buy (b-)” rating to a “buy (b)” rating in a report on Friday, July 24th. Bank of America raised their price objective on shares of Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a report on Monday, July 13th. Morgan Stanley boosted their target price on shares of Labcorp from $308.00 to $338.00 and gave the stock an “overweight” rating in a research note on Friday, July 31st. Finally, Robert W. Baird set a $352.00 price target on Labcorp in a research note on Friday, July 31st. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $336.36.

Labcorp Trading Down 0.7%

Shares of LH stock opened at $320.32 on Friday. The company has a quick ratio of 1.53, a current ratio of 1.80 and a debt-to-equity ratio of 0.69. The business has a fifty day simple moving average of $314.52 and a 200-day simple moving average of $283.17. The stock has a market cap of $25.98 billion, a P/E ratio of 26.49, a P/E/G ratio of 1.83 and a beta of 0.88. Labcorp has a fifty-two week low of $244.52 and a fifty-two week high of $341.80.

Labcorp (NYSE:LH) last released its earnings results on Thursday, July 30th. The medical research company reported $4.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.78 by $0.21. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The company had revenue of $3.73 billion for the quarter, compared to analyst estimates of $3.71 billion. During the same period in the prior year, the firm earned $4.35 EPS. The firm’s quarterly revenue was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. On average, analysts forecast that Labcorp will post 18.32 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Stockholders of record on Friday, August 28th were issued a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a dividend yield of 0.9%. The ex-dividend date was Friday, August 28th. Labcorp’s dividend payout ratio is presently 23.82%.

Insider Transactions at Labcorp

In other news, EVP Amy B. Summy sold 924 shares of the firm’s stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $306.74, for a total value of $283,427.76. Following the transaction, the executive vice president owned 6,956 shares of the company’s stock, valued at approximately $2,133,683.44. This trade represents a 11.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Kerrii B. Anderson sold 3,000 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $318.02, for a total transaction of $954,060.00. Following the completion of the sale, the director directly owned 6,563 shares of the company’s stock, valued at $2,087,165.26. The trade was a 31.37% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 8,919 shares of company stock valued at $2,826,593 in the last quarter. Insiders own 0.84% of the company’s stock.

Labcorp Company Profile

Labcorp (NYSE: LH), formerly Laboratory Corporation of America Holdings, is a global life sciences and laboratory services company headquartered in Burlington, North Carolina. The company provides diagnostic testing and related services to physicians, hospitals, health systems, employers, government agencies and consumers.

Its diagnostics business offers routine and specialty laboratory testing, including molecular, genetic, oncology, women’s health, infectious disease and pathology services.